Pompe Prevalence Study in Patients With Muscle Weakness Without Diagnosis (POPS)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Nice
ClinicalTrials.gov Identifier:
NCT00830583
First received: January 27, 2009
Last updated: December 7, 2011
Last verified: January 2009

January 27, 2009
December 7, 2011
January 2009
October 2011   (final data collection date for primary outcome measure)
Evaluate the prevalence of the Pompe disease among patients with progressive limb girdle muscular weakness and/or axial deficiency, and/or respiratory insufficiency. The diagnosis will be confirmed using DBS. [ Time Frame: during the first and the only visit ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00830583 on ClinicalTrials.gov Archive Site
  • Evaluate the relative sensibility of the diagnosis in the Pompe disease by muscular biopsy with histological methods (PAS and acid phosphatase). [ Time Frame: during the first and the only visit ] [ Designated as safety issue: No ]
  • Define the various methods of diagnosis for the Pompe Disease. [ Time Frame: during the first and the only visit ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Pompe Prevalence Study in Patients With Muscle Weakness Without Diagnosis
Pompe Prevalence Study in Patients With Muscle Weakness Without Diagnosis

An international consensual group recommends confirming the diagnosis of the Pompe disease after a dried blood spot (DBS) with a dosage of the enzymatic activity in other tissue. This strategy is currently used in the usual practice.

The aim is evaluate the prevalence of the Pompe disease among patients with progressive limb girdle muscular weakness and/or axial deficiency, and/or respiratory insufficiency. The diagnosis will be confirmed using DBS.

In Pompe disease, deficiency of the enzyme acid alpha-glucosidase (GAA) results in accumulation of glycogen within the lyososomes of numerous tissues and cell types especially in muscular cells.

Pompe disease is pan ethnic (but with increased prevalence in the afro-American and Chinese population). Pompe disease is rare with an estimated incidence of 1 in 40,000 births. In France so far, a hundred patients have been diagnosed. The difference of results between the epidemiologic studies published and the number of French patients diagnosed is caused by an under-diagnostic of this pathology, very rare and unknown.

The late onset type of the disease (from childhood to adult) is revealed by progressive muscle weakness generally beginning in proximal muscles of the legs. Respiratory muscle weakness is often the cause of death among patients having respiratory insufficiency.

Recognizing Pompe disease can be challenging, as signs and symptoms may be shared with other disorders (limb girdle muscular dystrophy, dystrophinopathy or inflammatory myopathy).

Muscle biopsies are often used to measure GAA activity and for histology in patients with muscle weakness. But glycogen accumulation in the muscles of patients varies with biopsy site, so the diagnosis of Pompe disease can be missed by using only a muscle biopsy. Fibroblasts can also serve as a source of material for research but cell culture facilities are not easy for clinicians and it takes several weeks to obtain confluent cultures. Then, assays that use blood to diagnose Pompe disease were developed. Therefore, a group of international clinicians and biologists met together in London in December 2006 and established an agreement concerning the various methods of this enzyme dosage. Recently, a test on a DBS (dried blood spot) has been developed. This test is not invasive, easy to collect and transport, requires small sample volume and provides rapid results. This international consensual group recommends confirming the diagnosis of the Pompe disease after a DBS with a dosage of the enzymatic activity in other tissue. This strategy is currently used in the usual practice.

Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Pompe's Disease
Procedure: blood test
There is only a blood test at the beginning.
1
pompe's disease suspected patient
Intervention: Procedure: blood test
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
400
October 2011
October 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age ≥ 8 years
  • The patient and/or the patient's legal representative has given their informed consent in writing before any study procedure is initiated
  • Patient with :

Limb girdle muscle weakness or axial weakness And/Or Respiratory insufficiency,With unknown etiology

  • Sporadic or familial case compatible with a autosomal recessive disorder
  • Patient with muscular biopsy (and specific immunologic analyses) without diagnosis.

Exclusion Criteria:

  • Patient with a confirmed and documented diagnosis of an etiologic muscular disease determined by the histological analysis (described in appendix 6) that must have been performed on muscle biopsy.
  • Patient familial background known with a X-link or a dominant transmission
  • Patient who have had confirmation of a Pompe disease by biochemical analysis and/or by molecular biology
  • Patient for whom an GAA enzymatic activity has already been performed and for which the result was normal.
Both
8 Years and older
No
Contact information is only displayed when the study is recruiting subjects
France
 
NCT00830583
08-PP-02
No
Centre Hospitalier Universitaire de Nice
Centre Hospitalier Universitaire de Nice
Not Provided
Principal Investigator: Claude Desnuelle CHU de Nice
Centre Hospitalier Universitaire de Nice
January 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP